- Home
- CNF vs ABVC Comparison
CNF vs ABVC Comparison
Compare CNF & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | ABVC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 26.7M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CNF | ABVC |
|---|---|---|
| Price | $2.03 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.5K | ★ 32.3K |
| Earning Date | 08-28-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $171.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.37 | $0.71 |
| 52 Week High | $6.49 | $3.06 |
Technical Indicators
Market Signals| Indicator | CNF | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 49.15 |
| Support Level | $1.74 | $0.92 |
| Resistance Level | $2.19 | $1.13 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 76.74 | 35.26 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.